Effect of interferon-gamma and TNF-alpha on MUC1 mucin expression in ovarian carcinoma cell lines.

Sean Clark,Bruce G Ward,Terry Hurst,Michael A Mcguckin

doi:10.1155/1994/480236

Sean Clark, Bruce G Ward + Show 2 more

Open Access

https://doi.org/10.1155/1994/480236

Copy DOI

Abstract

In view of the potential uses of cell surface tumour associated antigens in novel anticancer treatment, a study was designed to investigate whether the biological response modifiers interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) could effect the expression of an epitope on the tumour associated MUC1 epithelial mucin. Four ovarian carcinoma cell lines showing high (OAW42 and GG) and low (JAM and PE01) basal expression of MUC1 were treated with 10-1000 U/mL of IFN-gamma or TNF-alpha for one or five days. Changes in MUC1 expression in cells exposed to IFN-gamma or TNF-alpha were monitored using an ELISA technique with the monoclonal antibody BC2 which reacts with a core protein epitope on the MUC1 mucin, and then corrected for the number of viable cells present. TNF-alpha had little effect on MUC1 expression, but one or five days exposure to IFN-gamma significantly increased MUC1 expression (p < 0.01) in all cell lines including the two cell lines that initially showed little or no expression.

Highlights

Despite widespread use of platinum based chemotherapy less than 25% of patients with advanced ovarian carcinoma survive more than 5 years (Annual Report of the Results of Treatment of Gynecological Cancer, 1990)
This study aimed to investigate whether IFNy or tumour necrosis factor alpha (TNF-a) could effect the expression of a peptide epitope on MUC I in ovarian cancer cells showing high and low levels of basal expression
Mucin expression was quantitated by ELISA using antibody BC2, the mean ± s.d. is shown after subtraction of OD405 nm using a negative control antibody

Summary

Introduction

Despite widespread use of platinum based chemotherapy less than 25% of patients with advanced ovarian carcinoma survive more than 5 years (Annual Report of the Results of Treatment of Gynecological Cancer, 1990).

Objectives

Results

Discussion

Conclusion